Daily Briefing
Monday, February 9, 2026
The Vibe
AI's healthcare promise keeps bumping into messy clinical reality. Multiple studies today show ML models performing well in controlled settings—from IgA nephropathy risk prediction to cardiac MR super-resolution—but implementation stories remain sparse [1][2]. Meanwhile, the FDA's new leadership signals tougher enforcement on copycat drugs, suggesting regulators are getting serious about quality control [3].
Research
•Deep learning super-resolution reconstruction improves cardiac MR function analysis in clinical settings, though specific performance metrics weren't detailed in the cardiovascular imaging study [2]
•Machine learning models show promise for IgA nephropathy risk stratification, moving beyond conventional scoring systems toward precision nephrology approaches [1]
•Radiomics integration with brain network analysis demonstrates potential for Alzheimer's diagnosis and prognosis, combining standard and native imaging spaces [4]
•AI-driven osteoarthritis assessment tools are being evaluated for cartilage evaluation, though clinical validation remains ongoing [5]
Clinical Practice & Ops
•Eli Lilly dropped three pipeline drugs despite expecting $85-90B revenue by 2026, including a gene therapy from its $1B Prevail acquisition—harsh reminder that even giants cut losses [6][7]
•Bayer's asundexian showed 26% stroke reduction in Phase 3, directly challenging Bristol Myers Squibb and J&J's factor XIa inhibitors in a potential blockbuster market [8]
•Hospital supply chain costs will see IT-driven inflation while pharmacy price pressures ease from Q3 2026 to Q2 2027, according to Vizient forecasting [9]
Policy & Regulatory
•FDA Commissioner Makary pledged swift action against "mass-marketing illegal copycat drugs" following Hims' controversial Wegovy pill promotion [3]
•Trump signed funding legislation reviving the rare pediatric disease voucher program through 2026, restoring a key drug development incentive [10]
Industry & Products
•Angitia raised $130M Series D to advance bone disease bispecifics targeting Amgen's osteoporosis franchise [11]
•Amgen returned an OX40 autoimmune candidate to Kyowa Kirin, adding uncertainty to the troubled drug class [12]
One to Watch
FDA enforcement under Makary's leadership—his copycat drug crackdown suggests a more aggressive regulatory stance that could reshape how companies approach drug marketing and development.